Breathe Well Live Well
|
Regeneron speeds toward the FDA with its would-be asthma blockbuster
FierceBiotech Meanwhile, after meeting with the FDA, Regeneron now believes the agency will recognize an earlier Phase IIb asthma study as one of two required pivotal trials. In that trial, the highest doses of dupilumab significantly beat out placebo in improving … Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in … |
View full post on asthma – Google News
|
AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster
FierceBiotech Benralizumab–an IL-5 antibody–reduced the rate of asthma exacerbations, hitting the primary endpoint in the trial, says AstraZeneca ($AZN). But the study flagged weak results for the low end of the doses used in the trial, with the top dose doing … AstraZeneca share price: Novel drug shows positive results for severe asthma AstraZeneca's benralizumab succeeds in severe asthma |
View full post on asthma – Google News